Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH. Kjersem JB, et al. Among authors: yilmaz mk. BMC Cancer. 2014 May 19;14:340. doi: 10.1186/1471-2407-14-340. BMC Cancer. 2014. PMID: 24884501 Free PMC article. Clinical Trial.
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
Qvortrup C, Yilmaz M, Ogreid D, Berglund A, Balteskard L, Ploen J, Fokstuen T, Starkhammar H, Sørbye H, Tveit K, Pfeiffer P. Qvortrup C, et al. Ann Oncol. 2008 Jun;19(6):1154-9. doi: 10.1093/annonc/mdn002. Epub 2008 Feb 14. Ann Oncol. 2008. PMID: 18281265 Free article. Clinical Trial.
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Tveit KM, et al. Among authors: yilmaz mk. J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473155 Clinical Trial.
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM. Tarpgaard LS, et al. PLoS One. 2014 Feb 3;9(2):e87746. doi: 10.1371/journal.pone.0087746. eCollection 2014. PLoS One. 2014. PMID: 24498368 Free PMC article. Clinical Trial.
miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.
Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS. Schou JV, et al. PLoS One. 2014 Jun 18;9(6):e99886. doi: 10.1371/journal.pone.0099886. eCollection 2014. PLoS One. 2014. PMID: 24940606 Free PMC article. Clinical Trial.
The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer--a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG).
't Lam-Boer J, Mol L, Verhoef C, de Haan AF, Yilmaz M, Punt CJ, de Wilt JH, Koopman M. 't Lam-Boer J, et al. BMC Cancer. 2014 Oct 2;14:741. doi: 10.1186/1471-2407-14-741. BMC Cancer. 2014. PMID: 25277170 Free PMC article. Clinical Trial.
56 results